BeOne Medicines (ONC) Change in Accured Expenses (2015 - 2026)

BeOne Medicines (ONC) has reported Change in Accured Expenses for 12 consecutive years, with $212.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 65.98% year-over-year to $212.4 million in Q2 2026; TTM through Jun 2026 was $431.8 million, a 100.6% increase from a year earlier, with the FY2025 full-year figure at $311.8 million, up 179.97% from the prior year.
• Change in Accured Expenses was $212.4 million for Q2 2026 at BeOne Medicines, up from -$16.8 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $212.4 million in Q2 2026 and troughed at -$79.3 million in Q1 2024.
• A 5-year average of $46.9 million and a median of $53.9 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 2398.72% in 2022 and soared 397.7% in 2023, its largest moves.
• Over 5 years, Change in Accured Expenses stood at $44.0 million in 2022, then jumped by 195.51% to $130.0 million in 2023, then sank by 56.38% to $56.7 million in 2024, then surged by 157.2% to $145.9 million in 2025, then soared by 45.63% to $212.4 million in 2026.
• The last three Change in Accured Expenses figures came in at $212.4 million (Q2 2026), -$16.8 million (Q1 2026), and $145.9 million (Q4 2025), per Business Quant data.